GemVax & KAEL (082270) stock
KOSDAQ · Semiconductors & Semiconductor Equipment
As of Nov 16, 9:25 AM KST
- Market cap
- KRW 380.7 billion
- As of Nov 16, 2026
- P/E
- -31.14x
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- 4.47x
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 380.7 billion
- As of Nov 16, 2026
- P/E
- -31.14x
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- 4.47x
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-31.14x
Net loss — not comparable
P/B
—
P/S
4.47x
Earnings and dividend metrics▾
Earnings
EPS
-KRW 269
Earnings per share
BPS
-KRW 30
Book value per share
ROE
—
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at KRW 269 per share.
- BPS — net assets divided by the number of shares. Each share is backed by -KRW 30 of net assets.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 22.7 billion | KRW 1 billion | -KRW 9.9 billion | -9.2% |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 18.3 billion | -KRW 800 million | -KRW 1.5 billion | +47.6% |
| Q4 2025Consolidated · Filed Mar 20, 2026 | KRW 26.2 billion | KRW 7.5 billion | KRW 1.6 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 18 billion | KRW 700 million | -KRW 2.5 billion | +41.2% |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 25 billion | -KRW 1.5 billion | -KRW 1.6 billion | +47.6% |
| Q1 2025Consolidated · Filed May 15, 2025 | KRW 12.4 billion | -KRW 3 billion | -KRW 8.9 billion | -16.0% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 20, 2026 | KRW 81.5 billion | KRW 3.8 billion | -KRW 11.3 billion | — |
| FY2024Consolidated · Filed Mar 21, 2025 | KRW 62.7 billion | -KRW 38.3 billion | -KRW 87.2 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 10.34%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 330 million
- Previous 20-day average 18.46%
- Net short position
- 606,965 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 4,782,092 shares
- As of Nov 13, 2026 · 10.51% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 10.34% | KRW 330 million |
| Nov 12, 2026 | 20.32% | KRW 290 million |
| Nov 11, 2026 | 23.02% | KRW 390 million |
| Nov 10, 2026 | 19.54% | KRW 350 million |
| Nov 9, 2026 | 17.08% | KRW 540 million |
| Nov 6, 2026 | 21.38% | KRW 470 million |
| Nov 5, 2026 | 32.56% | KRW 550 million |
| Nov 4, 2026 | 23.01% | KRW 470 million |
| Nov 3, 2026 | 13.84% | KRW 210 million |
| Nov 2, 2026 | 29.13% | KRW 450 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- [Amended] Share Pledge Agreement Involving a Change of Largest Shareholder(Korean)Nov 12, 2026 · Change of Largest Shareholder
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Nov 11, 2026 · Insider Ownership Report
- Treasury Share Disposal(Korean)Nov 11, 2026
- Decision on Treasury Share Disposal(Korean)Nov 4, 2026 · Treasury Share Disposal
- [Amended] Share Pledge Agreement Involving a Change of Largest Shareholder(Korean)Nov 2, 2026 · Change of Largest Shareholder
- Short-term Borrowing(Korean)Oct 30, 2026
- Merger(Korean)Oct 30, 2026
- [Amended] Decision on Acquisition of Tangible Assets(Korean)Oct 30, 2026 · Investment
Filings with a published English version open in English; the rest link to the Korean original.
GemVax & KAEL (082270) stock information
KOSDAQ
GemVax & KAEL (082270) is listed on KOSDAQ. Its market capitalization is about KRW 380.7 billion. On trailing-twelve-month earnings the P/E ratio is -31.14. These figures are computed in-house from official filings and are reference information only.
GemVax & KAEL — frequently asked questions
- What is the P/E ratio of GemVax & KAEL (082270)?
- On a trailing-twelve-month basis, 082270 trades at a P/E ratio of -31.14. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of GemVax & KAEL?
- 082270 has a market capitalization of about KRW 380.7 billion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.